Hints and tips:
Related Special Reports
Related Topics
...Since taking the helm in 2012, Soriot has turned AstraZeneca into the second-largest company on the FTSE 100 index behind Shell....
...Emma Walmsley, chief executive of AstraZeneca’s British rival GSK, earned £12.7mn in 2023....
...AstraZeneca has a market capitalisation of £171bn....
...Late last year, AstraZeneca agreed to buy its first vaccine company, Icosovax, in a deal worth up to $1.1bn....
...AstraZeneca beat analysts’ estimates with 19 per cent growth in revenue in the first quarter of 2024, driven by stronger sales of its cancer drugs....
...Soriot said on Thursday that AstraZeneca’s deal activity would continue but “at a slower pace”....
...AstraZeneca has promised to increase its dividend by 7 per cent this year, ahead of a key shareholder vote on pay for its long-standing chief executive Pascal Soriot....
...AstraZeneca shareholders approved a potential £1.8mn pay rise for chief executive Pascal Soriot, despite a significant investor revolt against a pay increase advisers had called “excessive”....
...AstraZeneca has reported successful trial results for one of its top cancer drugs, in a boost to the drugmaker’s ambitions for its medication to be a treatment option for more than half of lung cancer patients...
...The writer is chair of AstraZeneca The AGM season is in full swing, and with it comes the usual set of controversies around remuneration....
...The chancellor said that AstraZeneca would invest £650mn in the UK to expand its manufacturing, after the government had encouraged the pharmaceutical company to increase its UK investment....
...AstraZeneca is starting its next 10-year cycle from a very different place....
...“Some of our loyal shareholders do expect cash dividends as an important part of total returns,” said AstraZeneca chair Michel Demaré at the AGM....
...The deal follows AstraZeneca’s $1bn acquisition of a French rare diseases start-up Amolyt last week....
...Shares in AstraZeneca dipped 1.1 per cent in morning trading....
...Sales of cancer drugs helped AstraZeneca to beat City expectations in 2023, as the FTSE 100 company forecast continued double-digit sales growth in 2024....
...These data reinforce that message,” said Susan Galbraith, executive vice-president of oncology R&D at AstraZeneca....
...AstraZeneca’s jab developed with Oxford university was widely used across the world, but sales fell more than 99 per cent to just $12mn in 2023....
...Muir had worked at AstraZeneca, which has more than 8,700 employees in the UK, since 1998....
...AstraZeneca already has expertise in RSV, as the drugmaker, in partnership with Sanofi, sells an antibody that protects infants from the disease....
...In August, AstraZeneca signed a deal with China’s CanSino Biologics for the production of its potential mRNA vaccines....
...The deal is expected to close in the first quarter of next year, AstraZeneca said....
...AstraZeneca raised its full-year sales guidance after an overall increase of 5 per cent in revenues offset the decline of Covid-19 products....
...AstraZeneca updated the label to warn recipients of the concern on April 7 and April 15....
...The agreement is part of AstraZeneca’s ambitious plans to replace traditional chemotherapy with a new generation of targeted drugs....
International Edition